Literature DB >> 430622

The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma.

.   

Abstract

We studied 454 patients with prostatic adenocarcinoma who were assigned a preliminary clinical stage on the basis of serum acid phosphatase, routine bone survey and physical examination. Subsequently, they were assigned a final clinical stage after radioisotopic bone scanning, lymphangiography and staging pelvic lymph node dissection. Only 53, 54, 57 and 26 per cent, respectively, of patients initially assigned the preliminary clinical stage of IB, II, III or IVA remained at that stage after the additional studies.

Entities:  

Mesh:

Year:  1979        PMID: 430622     DOI: 10.1016/s0022-5347(17)56761-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Localised carcinoma of the prostate: a paradigm of uncertainty.

Authors:  S S Sandhu; A V Kaisary
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

Review 2.  Radiologic imaging modalities, including magnetic resonance, for evaluating lymph nodes.

Authors:  G C Dooms; H Hricak
Journal:  West J Med       Date:  1986-01

3.  The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.

Authors:  S Ataus; A Citçi; B Alici; A U Onder; K Sönmezoğlu; A Erözenci; V Solok
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Prostate cancer imaging with a new monoclonal antibody: a preliminary report.

Authors:  E Sanford; R Grzonka; A Heal; M Helal; L Persky; I Tyson
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

5.  Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.

Authors:  Vidija Soerdjbalie-Maikoe; Rob C M Pelger; Guus A B Lycklama à Nijeholt; Jan-Willem Arndt; Aeilko H Zwinderman; Herman Bril; Socrates E Papapoulos; Neveen A T Hamdy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.